Pharmafile Logo

grass pollen allergy

- PMLiVE

Allergy Tx hit hard as birch pollen product stumbles

Shares in the company went into a steep decline this morning

- PMLiVE

Positive mid-stage trial gives Allergy’s investors some welcome relief

Its grass pollen vaccine showed a “highly significant” dose response

- PMLiVE

Consilium wins Allergy Therapeutics account

Will advise the firm on international investor relations

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links